| Nov 6 |
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Ionis reaches agreement on phase 3 trial design for Angelman candidate
|
| Nov 6 |
Ionis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 6 |
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
|
| Nov 6 |
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
|
| Nov 6 |
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
Ionis Pharmaceuticals: Q3 Earnings Snapshot
|
| Nov 6 |
Ionis Pharmaceuticals GAAP EPS of -$0.95 beats by $0.21, revenue of $134M beats by $4.07M
|
| Nov 6 |
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
|
| Nov 6 |
Ionis reports third quarter 2024 financial results
|
